Cover Image
市場調查報告書

梅尼爾氏症:開發平台分析

Meniere Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321916
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
梅尼爾氏症:開發平台分析 Meniere Disease - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 48 Pages
簡介

梅尼爾氏症是會引起非自主性暈眩的內耳障礙,會出現聽障、耳鳴、耳朵閉塞感等症狀。原因有過敏,病毒感染,頭部外傷,偏頭痛等。

本報告提供梅尼爾氏症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

梅尼爾氏症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

開發治療藥的企業

  • Orbis Biosciences, Inc.
  • Otonomy, Inc.
  • Quark Pharmaceuticals, Inc.
  • Sound Pharmaceuticals, Inc.
  • Synphora AB

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • betamethasone valerate ER
  • dexamethasone acetate SR
  • latanoprost
  • OR-105
  • QPHL-2
  • SPI-1005

最新的開發平台資訊

暫停中的計劃

產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8357IDB

Summary

Global Markets Direct's, 'Meniere Disease - Pipeline Review, H2 2016', provides an overview of the Meniere Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Meniere Disease
  • The report reviews pipeline therapeutics for Meniere Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects
  • The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Meniere Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Meniere Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meniere Disease Overview
  • Therapeutics Development
    • Pipeline Products for Meniere Disease - Overview
  • Meniere Disease - Therapeutics under Development by Companies
  • Meniere Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Meniere Disease - Products under Development by Companies
  • Meniere Disease - Companies Involved in Therapeutics Development
    • Orbis Biosciences Inc
    • Otonomy, Inc.
    • Quark Pharmaceuticals, Inc.
    • Sound Pharmaceuticals, Inc.
    • Synphora AB
  • Meniere Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • betamethasone valerate ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OR-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPHL-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-1005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Meniere Disease - Dormant Projects
  • Meniere Disease - Product Development Milestones
    • Featured News & Press Releases
      • Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients
      • Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
      • Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
      • Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease
      • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
      • Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease
      • May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease
      • Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients
      • Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease
      • Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study
      • Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease
      • Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference
      • Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In Meniere's Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Meniere Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Meniere Disease - Pipeline by Orbis Biosciences Inc, H2 2016
  • Meniere Disease - Pipeline by Otonomy, Inc., H2 2016
  • Meniere Disease - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
  • Meniere Disease - Pipeline by Sound Pharmaceuticals, Inc., H2 2016
  • Meniere Disease - Pipeline by Synphora AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Meniere Disease - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Meniere Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top